Praxis Precision Medicines: Breakthrough Neurology Pipeline and Regulatory Momentum Support Upside and Buy Rating

Francois Brisebois, an analyst from LifeSci Capital, maintained the Buy rating on Praxis Precision Medicines. The associated price target was raised to $534.00.

Francois Brisebois has given his Buy rating due to a combination of factors tied to Praxis Precision Medicines’ advancing neurology pipeline and recent regulatory momentum. He views the FDA’s Breakthrough Therapy Designation for ulixacaltamide in essential tremor as a major risk-reducing event, particularly because it validates the positive Phase 3 data and supports the drug’s potential to address a substantial, underserved patient population. Based on key opinion leader feedback suggesting meaningful uptake among U.S. essential tremor patients, he sees the company’s multibillion-dollar peak sales estimate as conservative, reinforcing a favorable long-term revenue outlook. The Breakthrough designation, along with an anticipated NDA filing in early 2026, also underpins his decision to raise the price target materially, reflecting increased confidence in both approval prospects and commercial execution.
Brisebois’s constructive stance is further supported by the progress of Praxis’s epilepsy-focused assets, which he views as additional value drivers that diversify risk. Relutrigine has delivered statistically significant seizure reduction data in clinical studies, and post-FDA interactions have supported a similar early-2026 NDA submission timeline, bolstering his conviction in its regulatory path. He also highlights the upcoming Phase 2/3 POWER1 data for vormatrigine in focal-onset seizures as a catalyst that appears relatively de-risked, given previously observed robust efficacy signals. Taken together, the multiple late-stage programs, strong clinical results, and favorable regulatory feedback justify his Buy rating and support an outlook of substantial upside from current levels.

Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Savara, and Dyne Therapeutics. According to TipRanks, Brisebois has an average return of -0.6% and a 38.30% success rate on recommended stocks.

In another report released today, Jefferies also maintained a Buy rating on the stock with a $450.00 price target.